Aerpio Therapeutics

OverviewSuggest Edit

Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.

Our lead programs include a Tie-2 activator for diabetic macular edema (DME) and a hypoxia-inducible factor 1-α (HIF1-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, recently completed a proof-of-concept, phase 2A study (TIME-2), and the HIF1-α stabilization program is rapidly progressing toward the clinic with first-in-human trials expected to start in early 2016.

TypePrivate
Founded2011
HQBlue Ash, OH, US
Websiteaerpio.com

Locations

Aerpio Therapeutics is headquartered in
Blue Ash, United States

Location Map

Latest Updates

Cybersecurity ratingAMore

Key People/Management at Aerpio Therapeutics

Steve Prelack

Steve Prelack

Chairman of the Board
Joseph Gardner

Joseph Gardner

President and Founder
Kevin Peters

Kevin Peters

Chief Scientific Officer and Chief Medical Officer
Mitchell Brigell

Mitchell Brigell

Consultant – VP Clinical
Barb Withers

Barb Withers

Vice President, Clinical Operations
Brandi Soldo

Brandi Soldo

Vice-President, Toxicology
Show more

Aerpio Therapeutics Office Locations

Aerpio Therapeutics has an office in Blue Ash
Blue Ash, OH, US (HQ)
The Landings II, 9987 Carver Rd #420
Show all (1)

Aerpio Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2011

Aerpio Therapeutics total Funding

$67.5 m

Aerpio Therapeutics latest funding size

$4.54 m

Time since last funding

5 years ago

Aerpio Therapeutics investors

Aerpio Therapeutics's latest funding round in April 2016 was reported to be $4.5 m. In total, Aerpio Therapeutics has raised $67.5 m
Show all financial metrics

Aerpio Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Aerpio Therapeutics Online and Social Media Presence

Embed Graph

Aerpio Therapeutics Frequently Asked Questions

  • When was Aerpio Therapeutics founded?

    Aerpio Therapeutics was founded in 2011.

  • Who are Aerpio Therapeutics key executives?

    Aerpio Therapeutics's key executives are Steve Prelack, Joseph Gardner and Kevin Peters.

  • Who are Aerpio Therapeutics competitors?

    Competitors of Aerpio Therapeutics include The Biomedical Engineering Society, Althea and CSL.

  • Where is Aerpio Therapeutics headquarters?

    Aerpio Therapeutics headquarters is located at The Landings II, 9987 Carver Rd #420, Blue Ash.

  • Where are Aerpio Therapeutics offices?

    Aerpio Therapeutics has an office in Blue Ash.

  • How many offices does Aerpio Therapeutics have?

    Aerpio Therapeutics has 1 office.